Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight
Ionis is transitioning from a licensing model to a commercial-stage biotech, investing heavily in its own drug launches and development pipeline. Upcoming catalysts include donidalorsen's FDA decision and olezarsen's Phase 3 data, both with significant peak sales potential in underserved markets. Despite ongoing losses and commercial execution risks, Ionis' validated platform and differentiated drugs offer compelling long-term growth opportunities.
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP & Chief Global Product Strategy Officer Beth Hougen - EVP, Finance & CFO Jonathan Birchall - SVP & Chief Commercial Officer Eugene Schneider - EVP, Chief Clinical Development & Operations Officer Conference Call Participants Jay Olson - Oppenheimer Gary Nachman - Raymond James Debjit Chattopadhyay - Guggenheim Jessica Fye - JPMorgan Chi Meng Fong - Bank of America Merrill Lynch Yaron Werber - TD Cowen David Lebowitz - Citi Mani Foroohar - Leerink Mike Ulz - Morgan Stanley Operator Good morning, and welcome to the Ionis First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $0.98 per share a year ago.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)
Ionis will announce its Q1 earnings on April 30th - in my view, the company is in a strong position and its current valuation of $4.5bn is far too low. The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG - a "blockbuster" indication. Management believes >$3bn revenues and >$2bn royalties + milestones may be achieveable long-term, with multiple new product launches for wholly-owned and partnered assets.
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi
In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.
